10.1007/s002210000591 Exp
Overweight adults with T2D who receive either semaglutide or standard glucose-lowering therapy (sitagliptin, empagliflozin, glipizide) Overweight adults without T2D who receive either semaglutide or usual anti-obesity drugs (Contrave, phentermine, Qsymia) The objective was to evaluate the risk of skeletal outcomes such as osteoporosis, osteoarthritis (hip and knee), gout, and other bone density disorders
However, studies have found improvements in patients self-reported quality of life after taking silymarin 2 perhaps due to decreased stress or self-perceived control over their health
Effects of Dietary Fibre Type on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Healthy Individuals
Flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders
I'm so happy to be back, people